A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit. 2) Willing to provide tumor tissue from newly obtained biopsy from tumor site. 3) Adequate hepatic function.

You may not be eligible for this study if the following are true:

  • 1) Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device according to the following time frame: For small molecule cytotoxins or other agents unlikely to interact with study drug: within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy. 2) Has not yet recovered (ie, grade =1 or baseline) from any acute toxicities resulting from prior therapy except for laboratory changes as described in inclusion criteria and patients with grade =2 neuropathy.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.